CNBC October 23, 2024
Key Points
– Novo Nordisk asked the Food and Drug Administration to prevent compounding pharmacies from making cheaper versions of its popular weight loss injection Wegovy and diabetes treatment Ozempic.
– The Danish drugmaker contends the medications are too complex for those manufacturers to make safely.
– The FDA still has to make a final decision on whether to bar those unapproved versions of semaglutide, the active ingredient in Ozempic and Wegovy.
Novo Nordisk on Tuesday asked the Food and Drug Administration to prevent compounding pharmacies from making unapproved and often cheaper versions of its popular weight loss injection Wegovy and diabetes treatment Ozempic, arguing that the medications are too complex for those manufacturers to make safely.
The...
Today's Sponsors
Today's Sponsor